prikaz prve stranice dokumenta Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review
  Preuzmi
PDF 467.04 KB
Znanstveni rad - Izvorni znanstveni rad
Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review
Croatian Medical Journal, 61 (2020), 4; 326-332. https://doi.org/10.3325/cmj.2020.61.326
Gamulin, Marija; Nham, Eric; Rkman, Deni; Antunac, Zrna; Golubić, Zrna; Likić, Robert

Citirajte ovaj rad

Gamulin, M., Nham, E., Rkman, D., Antunac, Z., Golubić, Z. i Likić, R. (2020). Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review. Croatian Medical Journal, 61. (4), 326-332. doi: 10.3325/cmj.2020.61.326

Gamulin, Marija, et al. "Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review." Croatian Medical Journal, vol. 61, br. 4, 2020, str. 326-332. https://doi.org/10.3325/cmj.2020.61.326

Gamulin, Marija, Eric Nham, Deni Rkman, Zrna Antunac, Zrna Golubić i Robert Likić. "Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review." Croatian Medical Journal 61, br. 4 (2020): 326-332. https://doi.org/10.3325/cmj.2020.61.326

Gamulin, M., et al. (2020) 'Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review', Croatian Medical Journal, 61(4), str. 326-332. doi: 10.3325/cmj.2020.61.326

Gamulin M, Nham E, Rkman D, Antunac Z, Golubić Z, Likić R. Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review. Croatian Medical Journal [Internet]. 01.08.2020. [pristupljeno 11.04.2024.];61(4):326-332. doi: 10.3325/cmj.2020.61.326

M. Gamulin, E. Nham, D. Rkman, Z. Antunac, Z. Golubić i R. Likić, "Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review", Croatian Medical Journal, vol. 61, br. 4, str. 326-332, Kolovoz 2020. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:651557. [Citirano: 11.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:651557
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review
AutorMarija Gamulin
AutorEric Nham
AutorDeni Rkman
AutorZrna Antunac
AutorZrna Golubić
AutorRobert Likić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Aim To assess diseases outcomes and tolerability of real-life second-line nivolumab in a series of metastatic renal cell carcinoma (mRCC) patients. ----- Methods This retrospective chart review involved prospectively monitored patients (named patient program) treated with second-line nivolumab for mRCC at the University Hospital Centre Zagreb from February 2016 to March 2018. ----- Results The study enrolled 30 patients, 5 of whom (16.7%) had a complete response. The mean ± standard deviation therapeutic response time to nivolumab treatment was 14.07 ± 8.92 months, with a minimum treatment duration of 2 months and a maximum of 24 months. The median duration of therapy was 17 months (mean: 15.8 months; range: 3-24 months), and 50% (n = 15/30) of patients remained alive at the end of follow up. The most common adverse events associated with nivolumab were fatigue (26.67%; n = 8/30), anemia (10.0%; n = 3/30), adrenal insufficiency (6.67%; n = 2/30: G1 = 1, G2 = 1), grade 2 pneumonitis (6.67%; n = 2/30), grade 2 neuropathy (6.67%; n = 2/30), rash (6.67%; n = 2/30: G1 = 1, G2 = 1), and hepatitis (3.33%; n = 1/30). ----- Conclusion The present study indicates acceptable patient responses and tolerability of nivolumab in mRCC.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaCroatian Medical Journal
Brojčani podacivol. 61, br. 4, str. 326-332
p-ISSN0353-9504
e-ISSN1332-8166
DOIhttps://doi.org/10.3325/cmj.2020.61.326
URN:NBNurn:nbn:hr:105:651557
Datum objave publikacije2020-08-01
URL dokumentahttp://www.cmj.hr/2020/61/4/32881430.htm
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2020-10-28 07:59:40